MedTrace Logo

Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.

NCT05415787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-03-01

No results posted yet for this study

Summary

Evaluation of technical feasibility for Homologous Recombination (HR) genes variants research on circulating tumor DNA (ctDNA) from plasma and urine of patients with a metastatic prostate cancer.

Conditions

Interventions

OTHER

Blood sample

2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.

OTHER

Urine sample

Urine sample is taken during the consultation carried out for the patient's care

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Matthias Tallegas · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-18
Primary Completion
2024-01-17
Completion
2024-01-18

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415787 on ClinicalTrials.gov